Lenacapavir long-acting

DRUG4 trials

Sponsors

ViiV Healthcare, Kelley-Ross & Associates, Inc., Duke University, Oswaldo Cruz Foundation

Conditions

Contact With or Exposure to Human Immunodeficiency VirusHIVHIV InfectionsHIV Pre-exposure ProphylaxisHIV Pre-exposure Prophylaxis UseHIV PreventionHIV Prevention ProgramHIV Prevention and Care

Phase 1

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Active, not recruitingNCT06970223

ViiV HealthcareHIV Infections

Start: 2025-04-22End: 2026-07-10Updated: 2025-11-28

Phase 4

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

Active, not recruitingNCT07210125

Kelley-Ross & Associates, Inc.HIV

Start: 2025-09-16End: 2027-06-30Target: 75Updated: 2026-04-02

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

RecruitingNCT07218211

Duke UniversityHIV Pre-exposure Prophylaxis, HIV Pre-exposure Prophylaxis Use, HIV Prevention +2

Start: 2026-01-13End: 2028-01-05Target: 100Updated: 2026-02-02

Unknown Phase

ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention

RecruitingNCT07497594

Oswaldo Cruz FoundationContact With or Exposure to Human Immunodeficiency Virus

Start: 2026-02-03End: 2029-09-01Target: 1500Updated: 2026-03-27